New Risk Markers for Cardiovascular Prevention

Cardiovascular Disease and Stroke (P Perrone-Filardi and S. Agewall, Section Editors)

Abstract

The importance of total cardiovascular (CV) risk estimation before management decisions are taken is well established. Models have been developed that allow physicians to stratify the asymptomatic population in subgroups at low, moderate, high, and very high total CV risk. Most models are based on classical CV risk factors: age, gender, smoking, blood pressure, and lipid levels. The impact of additional risk factors is discussed here, looking separately at the predictive increments of novel biomarkers and of indicators of subclinical atherosclerotic disease. The contribution of biomarkers to the total CV risk estimation is generally modest, and their usage should be limited to subjects at intermediate total CV risk. Detection of subclinical vascular damage may improve total CV risk estimation in asymptomatic subjects who are close to a threshold that could affect management decisions and in whom the chances of re-classification in a different risk category are great. There is, however, an urgent need for trials in which the value of using total CV risk estimation models is tested.

Keywords

Cardiovascular disease Prevention Risk factors Prediction 

References

Papers of particular interest, published recently, have beenhighlighted as: • Of importance •• Of major importance

  1. 1.
    Pyörälä K, De Backer G, Graham I, et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J. 1994;15:1300–31.PubMedGoogle Scholar
  2. 2.
    De Backer G, Ambrosioni E, Borch-Johnsen E, et al. European guidelines on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil. 2003;10:S1–S10.PubMedCrossRefGoogle Scholar
  3. 3.•
    Perk J, De Backer G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J. 2012;33:1635–701. Latest guidelines on CVD prevention by the 5th Joint Task Force of the ESC and other Societies, including recommendations on total CV risk estimation.PubMedCrossRefGoogle Scholar
  4. 4.
    Reiner Z, Catapano A, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2011;32:1769–818.PubMedCrossRefGoogle Scholar
  5. 5.•
    Goff Jr DC, Lloyd-Jones DM, Bennett G, et al. ACC/AHA Guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines. Circulation. 2013. doi:10.1161/01.cir.OOOO437741.48606.98. Latest guidelines from the AHA/ACC on CV risk assessment.PubMedCentralGoogle Scholar
  6. 6.
    Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation. 1991;83:356–62.PubMedCrossRefGoogle Scholar
  7. 7.
    D’Agostino Sr RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743–53.PubMedCrossRefGoogle Scholar
  8. 8.
    Conroy RM, Pyörälä K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987–1003.PubMedCrossRefGoogle Scholar
  9. 9.
    Woodward M, Brindle P, Tunstall-Pedoe H. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart. 2007;93:172–6.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ. 2008;336:1475–82.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Munster (PROCAM) study. Circulation. 2002;105:310–5.PubMedCrossRefGoogle Scholar
  12. 12.
    Ridker PM, Paynter NP, Rifai N, Gaziano JM, et al. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation. 2008;118:2243–51.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Ridker PM, Buring JE, Rifai N, et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007;297:611–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Romanens M, Ackermann F, Spence JD, et al. Improvement of cardiovascular risk prediction: time to review current knowledge, debates and fundamentals on how to assess test characteristics. Eur J Cardiovasc Prev Rehabil. 2010;17:18–23.PubMedCrossRefGoogle Scholar
  15. 15.
    Tunstall-Pedoe H. Cardiovascular Risk and Risk Scores: ASSIGN, Framingham, QRISK and others: how to choose. Heart. 2011;97:442–4.PubMedCrossRefGoogle Scholar
  16. 16.
    Reynolds TM, Twomey P, Wierzbicki AS. Accuracy of cardiovascular risk estimation for primary prevention in patients without diabetes. J Cardiovasc Risk. 2002;9(4):183–190.PubMedCrossRefGoogle Scholar
  17. 17.
    Bell K, Hayen A, McGeechan K, et al. Effects of additional blood pressure and lipid measurements on the prediction of cardiovascular risk. Eur J Prev Cardiol. 2012;19(6):1474–85.PubMedCrossRefGoogle Scholar
  18. 18.
    Siontis GC, Tzoulaki I, Siontis KC, et al. Comparisons of established risk prediction models for cardiovascular disease: systematic review. BMJ. 2012;344:e3318.PubMedCrossRefGoogle Scholar
  19. 19.••
    Pencina MJ, D’Agostino RB, Pencina KM, et al. Interpreting incremental value of markers added to risk prediction models. Am J Epidemiol. 2012;176:473–81. Excellent review on how to interprete the incremental value of biomarkers in estimating total CV risk. PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Pepe MS, Janes H, Longton G, et al. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic or screening marker. Am J Epidemiol. 2004;159:882–90.PubMedCrossRefGoogle Scholar
  21. 21.
    Cooney M, Dudina A, De Bacquer D, et al. How much does HDL cholesterol add to risk estimation? A report from the SCORE investigators. Eur J Cardiovasc Prev Rehabil. 2009;16:304–14.PubMedCrossRefGoogle Scholar
  22. 22.
    Kaptoge S, Di Angelantonio E, Pennells L, et al. C-reactive protein, fibrinogen and cardiovascular disease prediction. N Engl J Med. 2012;367:1310–20.PubMedCrossRefGoogle Scholar
  23. 23.
    Pencina MJ, D’Agostino Sr RB, D’Agostino Jr RB, et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157–72. discussion 207-12.PubMedCrossRefGoogle Scholar
  24. 24.
    Gotto Jr AM. Triglyceride as a risk factor for coronary artery disease. Am J Cardiol. 1998;82:22Q–5Q.PubMedCrossRefGoogle Scholar
  25. 25.
    Ridker PM. Fasting versus nonfasting triglycerides and the prediction of cardiovascular risk: do we need to revisit the oral triglyceride tolerance test? Clin Chem. 2008;54:11–3.PubMedCrossRefGoogle Scholar
  26. 26.
    Wormser D, Kaptoge S, Di Angelantonio E, et al. Separate and combined associations of body mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet. 2011;377:1085–95.PubMedCrossRefGoogle Scholar
  27. 27.
    van Dis I, Geleijnse JM, Kromhout D, et al. Do obesity and parental history of myocardial infarction improve cardiovascular risk prediction? Eur J Prev Cardiol. 2013;20:793–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Roberfroid D, San Miguel L, Thiry N. Novel serum biomarkers for the prediction of cardiovascular risk. Health Technology Assessment (HTA), Brussels: Belgian Health Care Knowledge Center ( KCE) 2013. KCE report 201. D/ 2013/ 10.273/22.Google Scholar
  29. 29.
    Buckley DI, Fu R, Freeman M, et al. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analysis for the U.S.Preventive Services Task Force. Ann Intern Med. 2009;151:483–95.PubMedCrossRefGoogle Scholar
  30. 30.
    Shah T, Casas JP, Cooper JA, et al. Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol. 2009;38:217–31.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med. 2006;145:21–9.PubMedCrossRefGoogle Scholar
  32. 32.•
    Yeboah J, McClelland RL, Polonsky TS, et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA. 2012;308:788–95. Using results from the Multi-Ethnic Study of Atherosclerosis ( MESA) the authors describe the incremental value of coronary artery calcium, ankle-brachial index, hs-CRP and family history in predicting CHD/CVD in intermediate-risk individuals.PubMedCrossRefGoogle Scholar
  33. 33.
    Kavousi M, Elias-Smale S, Rutten JH, et al. Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study. Ann Intern Med. 2012;156:438–44.PubMedCrossRefGoogle Scholar
  34. 34.
    Blankenberg S, Zeller T, Saarela O, et al. Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving and monograph (MORGAM) biomarker project. Circulation. 2010;121:2388–97.PubMedCrossRefGoogle Scholar
  35. 35.
    Melander O, Newton-Cheh C, Almgren P, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA. 2009;302:49–57.PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    Helfand M, Buckley DI, Freeman M, et al. Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S.Preventive Services Task Force. Ann Intern Med. 2009;151:496–507.PubMedCrossRefGoogle Scholar
  37. 37.•
    Zeller T, Tunstall-Pedoe H, Saarela O, et al. High population prevalence of cardiac tropinin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM Biomarker project Scottish Cohort. Eur Heart J. 2014;35:271–81. Recent publication with results of the predictive value of troponin I levels measured by a high-sensitivity assay in the general population.PubMedCrossRefGoogle Scholar
  38. 38.
    Kim HC, Greenland P, Rossouw JE, et al. Multimarker prediction of coronary heart disease risk: the Women’s health initiative. JACC. 2010;55:2080–91.PubMedCrossRefGoogle Scholar
  39. 39.
    Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355:2631–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Shlipak MG, Fried LF, Cushman M, et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA. 2005;293:1737–45.PubMedCrossRefGoogle Scholar
  41. 41.
    Folsom AR, Chambless LE, Ballantyne CM, et al. An assessment of incremental coronary risk prediction using C-Reactive Protein and other novel risk markers. Arch Intern Meed. 2006;166:1368–73.CrossRefGoogle Scholar
  42. 42.
    Zethelius B, Berglund L, Sundstrom J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008;358:2107–16.PubMedCrossRefGoogle Scholar
  43. 43.
    Wang TJ, Wollert KC, Larson MG, et al. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation. 2012;126:1596–604.PubMedCrossRefGoogle Scholar
  44. 44.
    Schneider HJ, Wallaschofski H, Völzke H, et al. Incremental effects of endocrine and metabolic biomarkers and abdominal obesity on cardiovascular mortality prediction. PLoS One. 2012;7:e33084.PubMedCentralPubMedCrossRefGoogle Scholar
  45. 45.
    Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med. 2001;344:1608–21.PubMedCrossRefGoogle Scholar
  46. 46.•
    Fowkes FGR, Murray GD, Butcher I. et al. (2014) Development and validation of an ankle-brachial index risk model for the prediction of CV events. With results from 18 cohort studies the authors developed and validated a Ankle-Brachial index prediction model incorporating the Framingham Risk Score and the ABI in one equation. Eur J Prev Cardiol 2014;21:310–320.Google Scholar
  47. 47.
    Greenland P, Alpert JS, Beller GA, et al. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guideline. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2010;122:e584–636.PubMedCrossRefGoogle Scholar
  48. 48.
    O’Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med. 1999;340:14–22.PubMedCrossRefGoogle Scholar
  49. 49.
    Elias-Smale SE, Kavousi M, Verwoert GC, et al. Common carotid intima-media thickness in cardiovascular risk stratification of older people: the Rotterdam Study. Eur J Prev Cardiol. 2012;19:698–705.PubMedCrossRefGoogle Scholar
  50. 50.
    Nambi V, Chambless L, Folsom A, et al. Carotid intima-media thickness and the presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk in Communities) study. J Am Coll Cardiol. 2010;55:1600–7.PubMedCentralPubMedCrossRefGoogle Scholar
  51. 51.
    Ras RT, Streppel MT, Draijer R. et al. Flow-mediated dilation and cardiovascular risk prediction: A systematic review with meta-analysis. Int J Cardiol 2012; ahead of print.Google Scholar
  52. 52.
    Peters SA, den Ruijter HM, Bots ML. The incremental value of brachial flow-mediated dilation measurements in risk stratification for incident cardiovascular events: A systematic review. Ann Med. 2012;44:305–12.PubMedCrossRefGoogle Scholar
  53. 53.
    Wilkinson IB, McEniery CM, Schillaci G, et al. ARTERY Society guidelines for validation of noninvasive haemodynamic measurement devices: part 1, arterial pulse wave velocity. Artery Res. 2010;4:34–40.CrossRefGoogle Scholar
  54. 54.
    Mattace-Raso FU, van der Cammen TJ, Hofman A, et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation. 2006;113:657–63.PubMedCrossRefGoogle Scholar
  55. 55.
    Silber S. Comparison of spiral and electron beam tomography in the evaluation of coronary calcification in asymptomatic persons. Int J Cardiol. 2002;82:297–8.PubMedCrossRefGoogle Scholar
  56. 56.
    Taylor AJ, Bindeman J, Feuerstein I, et al. Coronary calcium independently predicts incident premature coronary heart disease over measured cardiovascular risk factors: mean three-year outcomes in the Prospective Army Coronary Calcium (PACC) project. J Am Coll Cardiol. 2005;46:807–14.PubMedCrossRefGoogle Scholar
  57. 57.
    Greenland P, LaBree L, Azen SP, et al. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA. 2004;291:210–5.PubMedCrossRefGoogle Scholar
  58. 58.
    Erbel R, Möhlenkamp S, Moebus S, et al. Heinz Nixdorf Recall Study Investigative Group. Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall study. J Am Coll Cardiol. 2010;56:1397–406.PubMedCrossRefGoogle Scholar
  59. 59.
    Vliegenhart R, Oudkerk M, Song B, et al. Coronary calcification detected by electron-beam computed tomography and myocardial infarction. The Rotterdam Coronary Calcification Study. Eur Heart J. 2002;23:1596–603.CrossRefGoogle Scholar
  60. 60.
    Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med. 2008;358:1336–45.PubMedCrossRefGoogle Scholar
  61. 61.
    Criqui MH, Denenberg JO, Ix JH, et al. Calcium density of coronary artery plaque and risk of incident cardiovascular events. JAMA. 2014;311:271–8.PubMedCrossRefGoogle Scholar
  62. 62.
    Perrone-Filardi P, Achenbach S, Mohlenkamp S, et al. Cardiac computed tomography and myocardial perfusion scintigraphy for risk stratification in asymptomatic individuals without known cardiovascular disease: a position statement of the Working group on nuclear cardiology and cardiac CT of the European Society of Cardiology. Eur Heart J. 2011;32:1986–93.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Ghent University, Ghent, Belgium, University HospitalGentBelgium

Personalised recommendations